Similar articles

• Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.

  Brakemeier S, Bachmann F, Budde K. Brakemeier S, et al. Pediatr Nephrol. 2017 Jul;32(7):1137-1144. doi: 10.1007/s00467-016-3474-6. Epub 2016 Sep 1. Pediatr Nephrol. 2017. PMID: 27585680 Review.
• Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

  MacKeigan JP, Krueger DA. MacKeigan JP, et al. Neuro Oncol. 2015 Dec;17(12):1550-9. doi: 10.1093/neuonc/nov152. Epub 2015 Aug 19. Neuro Oncol. 2015. PMID: 26289591 Free PMC article. Review.
• mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis.

  Komotar RJ, Starke RM, Connolly ES, Sisti MB. Komotar RJ, et al. Neurosurgery. 2011 Apr;68(4):N24-5. doi: 10.1227/01.neu.0000395796.64099.76. Neurosurgery. 2011. PMID: 21792104 Review. No abstract available.
• Clinical and molecular insights into tuberous sclerosis complex renal disease.

  Siroky BJ, Yin H, Bissler JJ. Siroky BJ, et al. Pediatr Nephrol. 2011 Jun;26(6):839-52. doi: 10.1007/s00467-010-1689-5. Epub 2010 Dec 9. Pediatr Nephrol. 2011. PMID: 21152937 Review.
• Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.

  Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M. Wienecke R, et al. Am J Kidney Dis. 2006 Sep;48(3):e27-9. doi: 10.1053/j.ajkd.2006.05.018. Am J Kidney Dis. 2006. PMID: 16931204